A holistic analysis platform for assessing protein modification and functional activity

Linking Protein Modifications to Functional Impact. Protein modifications are critical for the efficacy, safety, and...

Midas Pharma and Biofidus join forces for integrated Biotech Solutions

Biofidus AG is now a member of the Midas group. With the acquisition of Biofidus,...

What are the publication dates for these items on the Biofidus News page?

FDA – Waives Clinical Efficacy Studies — Sep 26, 2025; A holistic analysis platform for assessing protein modification and functional activity — Jun 11, 2025; Midas Pharma and Biofidus join forces for integrated Biotech Solutions — Mar 25, 2025.

News

Publications

Screen, Select, Enhance: A joint evitria AG – Biofidus workflow for ADCC‑enhanced antibody development

News

Mar 20, 2026

Featured

FDA strengthens the role of analytical comparability in biosimilar development

Publications

May 19, 2026

Screen, Select, Enhance: A joint evitria AG – Biofidus workflow for ADCC‑enhanced antibody development

We collaborated with evitria AG on an integrated workflow that connects evitria’s high‑throughput antibody expression...

News

Mar 20, 2026

FDA strengthens the role of analytical comparability in biosimilar development

Analytical Comparability at the Center of Modern Biosimilar Development The U.S. Food and Drug Administration...

News

Sep 26, 2025

FDA – Waives Clinical Efficacy Studies

A New Era for Biosimilars: Powered by Analytics In a historic regulatory shift, the U.S....